2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of …

N Galiè, M Humbert, JL Vachiery, S Gibbs… - European heart …, 2016 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data

B Thoreau, L Mouthon - Autoimmunity Reviews, 2024 - Elsevier
Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary
hypertension classification, is a rare disease with a major prognostic impact on morbidity …

Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension

S Günther, X Jaïs, S Maitre, A Berezne… - Arthritis & …, 2012 - Wiley Online Library
Objective Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary
hypertension (PH) characterized by obstruction of small pulmonary veins. Pulmonary …

[PDF][PDF] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

N Galiè, M Humbert, JL Vachiery… - Polish Heart …, 2015 - journals.viamedica.pl
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Sex differences in response to tadalafil in pulmonary arterial hypertension

SC Mathai, PM Hassoun, MA Puhan, Y Zhou, RA Wise - Chest, 2015 - Elsevier
BACKGROUND Pulmonary arterial hypertension (PAH) is a progressive disease with high
rates of morbidity and mortality. Current therapies improve symptoms, functional capacity …

Wytyczne ESC/ERS dotyczace rozpoznawania i leczenia nadcisnienia plucnego w 2015 roku.

N Galiè, M Humbert, JL Vachiery, S Gibbs, I Lang… - Kardiologia …, 2015 - orbi.uliege.be
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease

F Perros, S Cohen-Kaminsky… - American journal of …, 2013 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease
(PVOD) both display occlusive remodeling of the pulmonary vasculature responsible for …

Update in systemic sclerosis-associated pulmonary arterial hypertension

MA Gashouta, M Humbert, PM Hassoun - La Presse Médicale, 2014 - Elsevier
Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic
sclerosis (SSc). Despite advances in treatment options for PAH, long-term prognosis …

Pulmonary veno-occlusive disease: the role of CT

G Mineo, D Attinà, M Mughetti, C Balacchi… - La radiologia …, 2014 - Springer
Objective The authors sought to evaluate the diagnostic accuracy of high-resolution
computed tomography (HRCT) in the detection of pulmonary veno-occlusive disease …

Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening

CP Denton, E Hachulla - European Respiratory Review, 2011 - Eur Respiratory Soc
Pulmonary arterial hypertension (PAH) is a relatively common complication of systemic
sclerosis (SSc) affecting 5–12% of patients, and its development is associated with …